

Liver Failure Induces a Systemic Inflammatory Response

Prevention by Recombinant N-Terminal Bactericidal/Permeability-Increasing Protein

Marja A. Boermeester,*
Alexander P. J. Houdijk,* Sybren Meyer,*
Miguel A. Cuesta,* Ben J. Appelmek,†
Robert I. C. Wesdorp,* Erik Hack,‡§ and
Paul A. M. Van Leeuwen*

From the Departments of Surgery,* Medical Microbiology,†
and Internal Medicine,‡ Free University Hospital; and
Central Laboratory of the Netherlands Red Cross Blood
Transfusion Services,§ Amsterdam, The Netherlands

The observed increased susceptibility of patients with fulminant hepatic failure for local and systemic infections has been hypothesized to be due to a failure of the hepatic clearance function and subsequent leaking of endogenous endotoxins into the systemic circulation. However, experimental evidence for such a systemic inflammation during liver failure due to endogenous endotoxemia is lacking. Therefore, we designed a study to clarify whether circulating endotoxins due to liver failure could lead to the development of systemic inflammation. In a rat model for liver failure induced by a two-thirds partial hepatectomy, we evaluated the course of circulating tumor necrosis factor and interleukin-6, changes in blood chemistry and hemodynamics, and histopathological changes in the lungs. Partially hepatectomized animals, but not sham-operated animals, demonstrated cardiac failure, increased levels of creatinin and urea, metabolic acidosis, high plasma levels of tumor necrosis factor and interleukin-6, and an influx of PMNs in the lungs—together indicating the development of a systemic inflammatory response. Continuous infusion of recombinant N-terminal bactericidal/permeability-increasing protein (rBPI₂₃), a well described endotoxin-neutralizing protein, prevented these inflammatory reactions. Ex vivo experiments with rat plasma samples confirmed

the presence of circulating endotoxins in partially hepatectomized rats as opposed to those treated with rBPI₂₃. Thus, our results indicate that the early phase of liver failure induces a systemic inflammatory response triggered by circulating endotoxins, which can be prevented by perioperative infusion of rBPI₂₃. (Am J Pathol 1995, 147:1428–1440)

Apart from its involvement in numerous metabolic and homeostatic processes, the liver plays a predominant role in the regulation of inflammatory responses, because it produces acute phase reactants, generates and metabolically inactivates inflammatory mediators, and clears bacteria and their products.¹ Up to 80 to 90% of the systemic phagocytic capacity consists of the phagocytic cells lining the liver sinusoids, the Kupffer cells.² Consequently, a decrease in hepatic phagocytic function significantly impairs the removal of circulating particles, in spite of a compensatory increase in the splenic and lung phagocytic capacity.^{3–6} The important role of the liver in the host defense is illustrated by observations that patients with liver failure are susceptible to local and systemic infections,^{7–10} frequently have a systemic endotoxemia,^{7–9,11,12} and may even develop clinical signs of sepsis.¹³

Earlier studies have found that hepatic failure can lead to leaking of endogenous endotoxins into the systemic circulation.¹⁴ The inflammatory sequelae of administration of a known amount of endotoxin have

Supported by grants from the Ludgardine Bouman/Jan Bakker Foundation, Amsterdam, The Netherlands; and XOMA Corp., Berkeley, CA.

Accepted for publication July 18, 1995.

Address reprint requests to MA Boermeester, MD, PhD, at her present address, Academic Medical Center, Department of Surgery (G4-114), Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

been described in numerous animal models. However, little is known about the systemic consequences of endogenously released endotoxins during liver failure. First, the exact nature of a supposed inflammatory host response after experimental liver failure has never been characterized. Second, it remains to be established to what extent endogenous endotoxins in models of liver failure contribute to hemodynamic and metabolic changes. For example, it is well known that patients with bacteremia do not necessarily suffer from sepsis, ie, the inflammatory response syndrome associated with clinical bacterial infection. Thus, the presence of circulating endotoxins as such does not inevitably lead to clinical manifestations.

Here we studied the development, extent, and prevention of an inflammatory host response and its clinical consequences in a rat model of liver failure induced by a two-thirds liver resection.¹ Various inflammatory and clinical parameters were analyzed in rats that received either continuous i.v. administration of the recombinant N-terminal fragment (rBPI₂₃)¹⁵ of bactericidal/permeability-increasing protein (BPI),^{16,17} a well described protein that specifically binds to and neutralizes lipopolysaccharides (LPS) *in vitro*^{15,18,19} and *in vivo*,^{20,21} or an inactive control protein (thaumatin) as opposed to sham-operated rats;² *ex vivo* experiments with rat plasma were used to detect the presence of circulating endotoxins in these rats. The results indicate that acute liver failure due to partial hepatectomy (phx) induces systemic inflammatory reactions in experimental rats, and that these reactions are significantly blunted by perioperative infusion of rBPI₂₃.

Materials and Methods

Animals

This study was carried out in accordance with the recommendations of the Guide for the Care of Laboratory Animals used in our institute. Male Wistar rats (n = 84, 230 to 250 g, Harlan CPB, Zeist, The Netherlands) were allowed to acclimatize to the laboratory environment for 5 days, during which time they had free access to water and rat chow (SRM-A; Hope Farms, Woerden, The Netherlands). The animals were housed under standard environmental conditions with a 12-hour light/dark cycle. Chow was withdrawn on the evening before surgery.

Experimental Protocol

The animals were randomized to receive a two-thirds phx or a sham operation, and a continuous i.v. infu-

sion of either recombinant N-terminal bactericidal/permeability-increasing protein (rBPI₂₃; XOMA Corp., Berkeley, CA) or thaumatin (XOMA Corp.), as an isotypical (isoelectric, iso-kd) inactive control protein. This resulted in four groups of animals: 1) sham-thaumatins (SH-CON, n = 20);² sham-rBPI₂₃ (SH-BPI, n = 20);³ phx-thaumatins (PHX-CON, n = 22); and⁴ phx-rBPI₂₃ (PHX-BPI, n = 22). Before the start of the treatment and surgical procedures, the animals were anesthetized using ether and placed in the supine position on a heating pad. First, a loading dose of the assigned treatment drug was given via the tail vein: 1 mg/kg rBPI₂₃ or 1 mg/kg thaumatin in 0.5 ml buffer solution (containing 20 mmol/L sodium citrate, 150 mmol/L sodium chloride; pH 5). Then, a polyethylene catheter (PE-50; Fisher Scientific, Springfield, NY) was placed via the right jugular vein into the superior caval vein, and subcutaneously tunneled to the interscapular region. Through a springwire (Instech Laboratories, Plymouth Meeting, MA), this i.v. line was connected to a swivel (Instech Laboratories) and a micro-infusion pump (Harvard Apparatus, Boston, MA). Placement of the catheter was done under aseptic conditions in a flow chamber using sterile equipment. Once the connection was established, a second loading dose of the assigned treatment drug, containing 2 mg/kg rBPI₂₃ or thaumatin in 1 ml (0.5 ml buffer solution plus 0.5 ml 0.9% (w/v) NaCl), was injected slowly into the i.v. line. Immediately thereafter, a continuous infusion of 0.2 mg/kg/hour rBPI₂₃ or thaumatin was started at an infusion rate of 500 μ l/hour. The dose and treatment regime used were based on previous studies in rats: 3 mg/kg rBPI₂₃ infused simultaneously (via a different vein) with 250 mg/kg LPS over 30 minutes, completely blocked induced cardiovascular effects.²¹ Based on previous direct measurements of plasma levels of endotoxin in partially hepatectomized rats,¹⁴ we estimated these levels to be <1 ng/ml. Therefore, the dose of rBPI₂₃ used in the present study was expected to be sufficient. Because of the rapid clearance of rBPI₂₃ from the circulation, equivalent to that of cytokines, we used two consecutive loading doses to reach sufficient plasma levels, one before placement of the infusion catheter and the other just before the operation, followed by a continuous i.v. infusion to maintain these levels during the entire observation period.

Subsequently, the rats received a two-thirds phx or a sham operation. All surgical procedures were performed between 9:00 AM and 11:00 AM. phx was performed according to the method of Higgins and Anderson,²² consisting of resection of the median and left hepatic lobes. The resection was performed

using a single vicryl ligature, which was carefully placed around the pedicles of these lobes using cotton wool sticks to prevent bleeding from the liver bed. Utilizing this method, no blood loss occurred during and after the operation. Sham animals underwent a midline laparotomy, and gentle manipulation and exteriorization of the median and left lobes, but no actual resection was performed. The incision was closed in two layers by vicryl sutures. The animals were then allowed to regain consciousness, and within 20 minutes they were able to move freely, with exception of the animals that were used for frequent blood sampling (see Blood Sampling section). All animals continued to receive their i.v. infusions. In addition, the animals remained fasted and received no fluids orally during the experiment.

Six animals of each group were used to obtain serial blood samples during a 4-hour period, after which they were sacrificed by a lethal injection of sodium pentobarbital (100 mg/kg). Eight animals of each group were included in the protocol for assessment of hemodynamic parameters, measured at 4 hours after the operation. Frequent blood sampling was not done in these animals, as this may interfere with hemodynamic parameters. In the remaining animals of each group (SH-CON and SH-BPI, each $n = 6$; PHX-CON and PHX-BPI, each $n = 8$) treatment was continued for a 24-hour period. After 24 hours, these animals were reanesthetized using ketamine HCL (50 mg/kg i.p.) and a small arterial blood sample (200 μ l) was taken for comparative interleukin-6 (IL-6) analysis. Thereafter, the lungs were removed for histological studies. Rats were killed by an overdose of sodium pentobarbital as described.

Blood Sampling

From six animals of each group, small quantities of arterial blood (250 μ l) were drawn before and 1, 2, 3, and 4 hours after the operation for determination of plasma levels of cytokines, hematocrit (at $t = 4$ hours only) and, additionally, for stimulation experiments of human whole blood. For frequent blood sampling, anesthesia was maintained using 50 mg/kg ketamine HCL i.p. and a small arterial line was placed in the femoral artery. Heparinized blood samples were immediately placed on ice, and plasma was obtained by centrifugation of blood for 15 minutes at $1500 \times g$ at 4°C. All plasma samples were harvested in a laminar flow cabinet to prevent contamination, and stored in aliquots at -70°C until tested.

The eight animals of each group that were randomized for the hemodynamic measurements were only sampled after these experiments, ie, at 4 hours

after sham operation or phx. Arterial blood samples were taken for chemical blood analysis as well as determination of plasma levels of tumor necrosis factor (TNF) and IL-6. Cytokine levels assessed in these animals were subsequently compared with those of the animals from which samples had been taken more frequently.

Hemodynamic Measurements

For hemodynamic measurements, animals were anesthetized using ketamine HCL (50 mg/kg i.p.) and placed in the supine position on a heating pad that maintained rectal temperature at 37°C. The trachea was intubated with a small polyethylene tube (PE-240; Fisher Scientific) to facilitate breathing. The right carotid artery and left femoral artery were cannulated using PE-50 tubing. Both catheters were connected to P23Db Statham pressure transducers to monitor placement of the carotid catheter into the left cardiac ventricle and to measure femoral artery blood pressure. After these procedures, rats were allowed to stabilize for 20 minutes. Before the hemodynamic measurements, 150 ml of blood was drawn from the femoral artery for hematological, pH, and blood gas analysis. Thereafter, mean arterial blood pressure (MAP) and heart rate were recorded continuously during 1 minutes.

Cardiac output (CO) measurements were performed as part of an organ blood flow study (to be published separately) using the radiolabeled microsphere method, as previously described.^{23,24} Briefly, 0.7 ml of a 0.9% NaCl suspension containing 1.0 to 1.5×10^5 microspheres labeled with ⁴⁶Sc (New England Nuclear, Boston, MA) were injected into the left ventricle over a period of ~20 seconds. A reference blood sample was obtained from the femoral artery by a calibrated roller pump starting 5 seconds before microsphere injection, at a rate of 0.50 ml/minute for 90 seconds. After the microsphere injection, arterial blood pressure was recorded once more, to assure that the procedure had not been performed during significant hemodynamic changes nor had caused such changes. Thereafter, blood was drawn from the femoral artery, and the animals were killed by an intra-arterial injection of pentobarbital sodium (100 mg/kg). After verification of the position of the left ventricular catheter, the heart was dissected free and weighed. Radioactivity was counted in a well type γ counter (LKB-1280, Ultragamma, Wallac, Turku, Finland). Count rates were corrected for natural background and counter dead time. CO was calculated according to the equation $CO = Fa (Q_{tot}/Q_a)$, where Fa is reference flow, Q_{tot} is

the total injected radioactivity, and Q_a is the radioactivity in the reference sample. Reference flow was computed from the weight of blood in the sample syringe (assuming a whole blood density of 1.069 g/ml) and the duration of withdrawal. Arterial blood flow to the heart (coronary arteries) was calculated using the equation $F = Fa (Q_o/Q_a)$, where Q_o is the count rate in the organ to be measured.

Hematological and Chemical Blood Analysis

To determine acid–base balance, pH was measured as part of a blood gas analysis using a commercial blood gas analyzer (ABL 330, Radiometer, Copenhagen, Denmark). Hemoglobin, hematocrit, total white blood cell (WBC) numbers, and chemical parameters were analyzed by automated laboratory analysis. Ammonia levels were assayed by a standard enzymatic method.

Histological Studies

Twenty-four hours after phx or sham operation the lungs were removed. Sections of the tissues were made by conventional methods and chloroacetate-esterase (Lederstain) was used for staining of polymorphonuclear neutrophils (PMNs). All sections were examined in a blinded fashion.

TNF and IL-6 Bioassays

Biological TNF activity was measured as described by Espevik and Nissen-Meyer,²⁵ using the murine fibrosarcoma WEHI 164 clone 13 cell line. Briefly, 4×10^4 WEHI cells/100 μ l were incubated in RPMI 1640 containing 100 U/ml penicillin, 100 μ l/ml streptomycin, L-glutamine, 10% (v/v) fetal calf serum (FCS), and 1 μ g/ml actinomycin D in the presence of serial dilutions of samples to be tested. After 18 hours at 37°C, cytotoxicity was assessed with the MTT (3-(4,5-dimethylthazol-2-yl)-2,5-diphenyl tetrazolium bromide) method, as previously described.²⁶ Serial dilutions of samples to be tested were compared to a standard curve of recombinant mouse TNF and expressed as units per ml. One unit per ml is the amount of TNF that kills 50% of the cells. The lower detection limit of the assay at the dilutions of samples used was 1 U/ml.

IL-6 bioactivity was measured with the murine hybridoma B cell line B9, as described previously.^{27,28} In short, 5000 B9 cells in 200 μ l flat-bottomed wells were grown in Iscove's modified Dulbecco's medium (IMDM) containing 100 U/ml penicillin, 100 μ g/ml streptomycin, 5×10^{-5} mol/L 2-mercaptoethanol,

and 5% (v/v) FCS in the presence of serial dilutions of samples to be tested. After 68 to 72 hours cells were labeled with 7.4 kBq of [³H]thymidine (74 GBq/mmol), and thereafter the radioactivity incorporated in the nuclei was counted. Results were compared with a standard curve of natural IL-6 from cultured human monocytes stimulated with endotoxin, and expressed as units/ml. One unit/ml of IL-6 is the concentration that induces half-maximal thymidine incorporation in the assay. The lower detection limit of the assay at the dilutions of samples used was 10 U/ml.

Endotoxin-Induced Stimulation of Human Whole Blood Cultured With ex Vivo Rat Plasma

To assess the presence of biologically active endotoxins in the plasma of each rat during the treatment regime, plasma samples from each group of animals, taken before and 1 and 2 hours after surgery, were tested for their potency to induce the release of pro-inflammatory cytokines by human mononuclear cells. From each group, samples from six animals taken at the indicated time points were assayed. The results of each animal were compared to its own baseline ($t = 0$ hours) value.

Human whole blood of healthy volunteers was cultured at a final dilution of 1:10 in 200 μ l flat-bottom wells in endotoxin-free IMDM containing 100 U/ml penicillin, 100 μ l/ml streptomycin, and 0.1% (v/v) endotoxin-free FCS, in the presence of serial dilutions of rat plasma samples to be tested. Each sample was tested alone and in the presence of either 5 μ g/ml α CD14 MAb (α CD14.22; Central Laboratory of the Netherlands Red Cross Blood Transfusion Services (CLB), Amsterdam, The Netherlands), 2 μ g/ml rBPI₂₃ or 2 ng/ml polymyxin B (Sigma Chemical Co., St. Louis, MO). After incubation for 18 hours at 37°C, culture supernatants were harvested and stored at –70°C until tested for the presence of cytokines. As a control, normal rat plasma containing LPS (*Escherichia coli* 055:B5) at concentrations of 0.1 to 1000 pg/ml, was repeatedly tested under similar conditions and in the same assay as the experimental samples to validate the results. In another control experiment, the effect of α CD14 MAb, rBPI₂₃, polymyxin B, and polyclonal α TNF (CLB, α TNF-514) antibody on cytokine induction by recombinant human TNF- α (courtesy of Dr. A. Creasey, Chiron Corp., Emeryville, CA) was assessed in human whole blood in the presence of normal rat plasma.

TNF- α in the supernatant was measured by a sandwich-type enzyme-linked immunosorbent assay

(ELISA) using two monoclonal antibodies (MAbs, CLB, Department of Immune Reagents) raised against recombinant human TNF- α . One MAb (MAb CLB-TNF α -7) was used for coating at a concentration of 2 μ g per ml. The other MAb (MAb CLB-TNF α -5) was biotinylated and used in combination with streptavidin poly-horseradish peroxidase conjugate (CLB, Department of Immune Reagents) to detect bound TNF- α . Stimulated human mononuclear cell supernatant was used as a standard for the assay. The amount of TNF- α present in this supernatant was assessed by comparison with purified recombinant human TNF- α . Results were expressed as pg per ml by reference to this standard.

IL-6 concentration in the supernatant was quantified with an ELISA modified from that described in detail before.²⁹ Briefly, purified monoclonal anti-human-IL-6 antibody (MAb CLB-IL6-16) was used as a capture antibody, and biotinylated sheep antibodies in combination with streptavidin poly-horseradish peroxidase conjugate were used to detect bound IL-6. Results were expressed as pg per ml by reference to a standard consisting of recombinant human IL-6.³⁰

IL-8 was measured with a sandwich-type ELISA modified from that described previously³¹; monoclonal anti-human-IL-8 antibody (MAb CLB-IL8/1) and biotinylated affinity purified sheep anti-IL-8 antibodies were used as capture and detecting antibodies, respectively. Polymerized horseradish peroxidase conjugated to streptavidin was used to quantify bound biotinylated antibodies. Results were compared with those obtained with dilutions of recombinant human IL-8 and expressed as pg per ml.

All samples were assayed in duplicate in the same culture experiment using blood from one healthy donor, and this was repeated using blood from another donor, to assess donor-dependent variability. All ELISAs used had interassay variation coefficients of <15%, as was estimated from the variation of dose-response curves obtained on at least three different days over a three-month period. All supernatants were tested within one assay procedure to minimize the interassay variation for each cytokine.

Statistical Methods

The data are expressed as means \pm SEM. The non-parametric Mann-Whitney *U* Test was used to assess the significance of differences between groups. Analysis of variance for repeated measures was used to assess significant changes in parameters in the course of the observation period. A difference was considered significant at $P < 0.05$ (two-tailed).

The Mann-Whitney *U* Test was then used to determine the significance of the differences between groups. Data were analyzed with a commercial statistical package (Stat-View; Abacus Concepts, Inc., Berkeley, CA).

Results

Systemic Hemodynamics

Repeated pilot experiments involving continuous measurement of MAP, heart rate, and CO during the first 6 hours after surgery and periodically over the next 18 hours, revealed that the nadir of hemodynamic changes occurred 4 hours after liver resection. In these pilot experiments, an arterial pressure transducer instead of the microsphere method was used to assess CO, enabling us to perform frequent measurements in the same animals. Decreases in MAP, heart rate and CO were initiated after 2 hours, reaching a nadir after 4 hours, and had almost disappeared after 6 to 8 hours.

Rats receiving a two-thirds phx showed significant decreases of MAP and heart rate of 27% and 19%, respectively (both $P < 0.005$) at 4 hours after surgery, whereas CO decreased by 43% ($P < 0.005$) as compared with sham animals. rBPI₂₃ treatment in phx rats prevented these changes in MAP, heart rate, and CO, resulting in values equivalent to those of sham animals. rBPI₂₃ had no effect on these parameters in sham rats (Figure 1).

The blood supply to the heart tissue remained unchanged after phx: 4.76 ± 1.22 and 4.93 ± 0.67 ml \cdot minutes⁻¹ in sham and phx animals, respectively. When the blood flow was calculated per gram of heart tissue, again no difference was observed: 6.07 ± 1.61 and 6.72 ± 0.88 ml \cdot minutes⁻¹ \cdot g⁻¹ in sham and phx animals, respectively. Infusion of rBPI₂₃ had no significant effect on these parameters in either sham or phx animals. The hypotension in the phx animals apparently had induced a compensatory redistribution of blood flow, because these animals showed a 62% increase in the proportion of CO that was distributed to the heart tissue via the coronary arteries ($P < 0.05$). In rBPI₂₃-treated phx animals, CO distribution to the heart tissue was similar to that of the sham group.

Histological Studies

The lungs are frequently involved in systemic inflammatory reactions. We therefore investigated possible inflammatory changes in this organ. All phx animals showed a significant number of PMNs infiltrating the




Figure 1. Cardiac function. Hemodynamic parameters of partially hepatectomized and sham rats treated with rBPI₂₃ or an isotypical inactive control protein (thaumatin). Results are expressed as means ± SEM. **P* < 0.005, by the Mann-Whitney U Test.

lungs at 24 hours after the operation (Figure 2 A and B), which was largely abrogated by rBPI₂₃ treatment (Figure 2C). Furthermore, in the phx group some marginating neutrophils and intravascular accumulation of PMNs were found in the lungs as well as some edema of the alveolar septa, whereas all rBPI₂₃-treated phx rats showed virtually none of these morphological changes. Neither rat of the control group (sham-operated with or without rBPI₂₃) had an inflammatory infiltrate in the lungs (Figure 2D).

Blood Chemistry

Chemistry data as measured 4 hours after the surgical procedure are shown in Table 1. After phx, he-




Figure 2. Lung morphology. Histological appearance of the lungs obtained 24 hours after phx. (A) Section of the lung from a control-treated hepatectomized rat, showing PMN accumulation and neutrophil aggregates (PHX-CON; 155×). (B) Higher magnification (410×) of A, showing neutrophil margination (arrowhead) and intravascular accumulation of PMNs (arrow). (C) Section of the lung from a rBPI₂₃-treated hepatectomized rat, showing mainly erythrocytes in the alveolar capillaries (PHX-BPI; 155×). (D) Section of the lung from a sham operated rat with normal lung morphology (SH-CON; 155×).

moglobin concentration and hematocrit both increased (*P* < 0.05). In addition, arterial blood pH and glucose levels had significantly declined as compared with sham values (*P* < 0.05 and *P* < 0.01, respectively). Levels of creatinin and urea (both *P* < 0.05), as well as of hepatic enzymes (aspartate aminotransferase and alanine aminotransferase), bilirubin, and ammonia, and total WBC numbers (all *P* < 0.005) were increased at 4 hours after liver resection. rBPI₂₃ treatment in phx animals resulted in significantly reduced creatinin levels and total WBC numbers, although the latter were still significantly higher than sham levels. rBPI₂₃ also reduced the fall in glucose levels and prevented the fall of pH in phx animals. Conversely, the pH in these animals was slightly higher than in sham animals. Urea levels in PHX-BPI animals tended to be lower than those of the PHX-CON group. rBPI₂₃ treatment had no significant effect on changes in hepatic enzymes, bilir-

Table 1. Blood Chemistry

	SH-CON	SH-BPI	PHX-CON	PHX-BPI
Hgb (mmol/L)	7.8 ± 0.4	7.6 ± 0.2	9.0 ± 0.3*	7.8 ± 0.3
Hct	0.41 ± 0.02	0.40 ± 0.01	0.45 ± 0.02*	0.40 ± 0.01
WBC (×10E9/L)	4.9 ± 0.9	5.2 ± 0.5	12.0 ± 1.5**	8.0 ± 0.9†
Arterial pH	7.33 ± 0.01	7.31 ± 0.01	7.26 ± 0.03*	7.39 ± 0.02†
Creatinin (μmol/L)	33 ± 2	34 ± 2	43 ± 4*	31 ± 2
Urea (mmol/L)	6.2 ± 0.6	5.7 ± 0.5	9.4 ± 0.5*	8.0 ± 0.4
AST (U/L)	66 ± 2	73 ± 4	622 ± 64**	689 ± 90**
ALT (U/L)	21 ± 1	28 ± 3	443 ± 69**	462 ± 128**
Bilirubin (μmol/L)	2 ± 0.1	2 ± 0.3	9 ± 1.4**	10 ± 2.7**
Ammonia (μmol/L)	104 ± 14	92 ± 7	227 ± 16**	198 ± 13**
Glucose (mmol/L)	8.3 ± 0.4	8.1 ± 0.4	6.6 ± 0.4*	7.3 ± 0.5

Blood analysis at 4 hours after a partial hepatectomy or sham operation of animals treated with either rBPI₂₃ or an isotypical inactive control protein (thaumatin). **P* < 0.05 versus SH-CON or SH-BPI; ***P* < 0.005 versus SH-CON and SH-BPI; †*P* < 0.05 versus SH-CON or SH-BPI, and also significantly different from PHX-CON (*P* < 0.05).

bin, and ammonia, as determined 4 hours after surgery.

Course of Cytokines

Sham-operated animals showed a modest increase in TNF levels at *t* = 1 hour that lasted for at least 2 hours. From *t* = 4 hours on, levels of TNF were no longer detectable in the plasma or near the detection limit of the assay. In control-treated phx rats, a sharp rise in TNF levels was found at *t* = 2 hours (74.8 ± 16.1 U/ml; *P* < 0.01 versus sham), which rapidly declined thereafter to reach values of 6.8 ± 2.3 U/ml 4 hours after the resection (Figure 3A). Conversely, in the rBPI₂₃-treated phx animals, plasma levels of TNF were undetectable except in two animals, which had detectable TNF concentrations at only one time point (*t* = 3 hours; 1.9 and 2.9 U/ml). The difference in TNF concentrations between rBPI₂₃-treated and control-treated phx animals was highly significant at *t* = 2 hours (*P* < 0.001) and significant at subsequent time points (*P* < 0.01). During the entire observation period, TNF levels of rBPI₂₃-treated phx rats also were lower than those of sham rats. In contrast, rBPI₂₃ treatment had no effect on the low TNF levels found in sham-operated animals (Figure 3A).

After the sham procedure, an early although moderate rise of IL-6 was found from *t* = 1 hour on. These levels were not affected by rBPI₂₃ treatment in sham animals. In control-treated phx rats, IL-6 levels demonstrated a steady increase from *t* = 2 hours on, reaching peak levels of 2119 ± 396 U/ml at *t* = 4 hours (*P* < 0.005 versus sham). rBPI₂₃ treatment in phx rats yielded significantly lower levels of IL-6 compared with control treatment (*P* < 0.005 at *t* = 4 hours). Only at *t* = 3 hours, IL-6 levels in rBPI₂₃-treated phx rats were higher compared with sham rats (*P* < 0.05; Figure 3B).




Figure 3. Cytokine levels. Plasma levels of TNF (A) and IL-6 (B) as assessed by WEHI and B9 bioassay, respectively. Results are expressed as means ± SEM. PHX-CON (□), PHX-BPI (■), SH-CON (○), SH-BPI (●). *PHX-CON versus PHX-BPI: *P* < 0.01 for TNF and *P* < 0.05 for IL-6; **PHX-CON versus PHX-BPI: *P* < 0.001 for TNF and *P* < 0.005 for IL-6; #SH-CON or SH-BPI versus PHX-BPI: *P* < 0.05; ##SH-CON or SH-BPI versus PHX-BPI: *P* < 0.005; ###SH-CON or SH-BPI versus PHX-CON or PHX-BPI: *P* < 0.01, by the Mann-Whitney U Test.

Stimulation of Human Whole Blood by Rat Plasma

To assess whether the observed changes after phx were due to circulating endotoxins, we examined the potency of rat plasma, taken before or after the hepatectomy or sham operation, to induce the release of cytokines in human whole blood. Using the experimental conditions described in Materials and Methods, 1 and 100 pg/ml LPS added to human whole blood resulted in a TNF- α concentration in the supernatant of 145 ± 38 and 634 ± 112 pg/ml, respectively, in the presence of 15% (v/v) normal rat plasma. This volume of normal rat plasma was equal to that used in the *in vitro* experiments with plasma from the experimental animals. Addition of α CD14 MAb, rBPI₂₃, and to a lesser extent polymyxin B (used at the concentrations described in Materials and Methods) resulted in an almost complete inhibition of TNF- α , IL-6, and IL-8 levels in the supernatant induced by LPS concentrations up to 100 pg/ml (data not shown). Incubation of human whole blood with plasma of sham rats gave rise to TNF- α levels in the supernatant ranging from 117 to 255 pg/ml. When α CD14 MAb, rBPI₂₃, or polymyxin B were added to cultures with sham plasma, levels of TNF- α as well as those of IL-6 and IL-8 in the supernatant were not significantly affected. Supernatant cytokine levels generated by rTNF- α added to cultures in the presence of normal rat plasma were not affected by α CD14 MAb, rBPI₂₃, or polymyxin B as opposed to polyclonal α TNF, consistent with the specific anti-LPS activities of the former three reagents.

Incubation of human whole blood with plasma of control-treated phx rats taken 1 and 2 hours after the resection, yielded significantly higher levels of human TNF- α in the supernatant as compared with plasma taken before the resection (Figure 4; both $P < 0.05$) or plasma of sham rats (both $P < 0.05$). TNF- α levels induced by phx plasma of $t = 1$ hour were consistently higher than those of phx plasma taken at $t = 2$ hours (Figure 4). In contrast, no significant increase in supernatant TNF- α levels was measured when plasma of rBPI₂₃-treated rats, taken at $t = 1$ (Figure 4) or $t = 2$ hours (data not shown) was tested, levels being the same as obtained with their preoperative plasma, and nearly equal to the levels found with plasma of sham-operated rats (both $P = NS$).

When α CD14 MAb, rBPI₂₃, and polymyxin B was added to the cultures and incubated with plasma of control-treated phx rats taken at 1 or 2 hours, the supernatant TNF- α concentrations were reduced to levels equal ($P < 0.05$ for α CD14 MAb and rBPI₂₃,




Figure 4. Endotoxin-induced stimulation of human whole blood cultured with ex vivo rat plasma. Induction of TNF- α in cultures of human whole blood by plasma of control-treated or rBPI₂₃-treated phx rats taken before and 1 or 2 hours after the resection. TNF- α induced by PHX-CON plasma of $t = 1$ and $t = 2$ hours are significantly higher than that of plasma taken before the resection and plasma of PHX-BPI animals at any given time point (both $P < 0.05$, by analysis of variance for repeated measures). PHX-CON, $t = 0$ (+), $t = 1$ (■), and $t = 2$ hours (○); PHX-BPI, $t = 0$ (Δ) and $t = 1$ hour (▼).

compared with levels induced by phx plasma alone) or nearly equal ($P = 0.06$ for polymyxin B) to those induced by baseline ($t = 0$ hours) plasma (Figure 5A). In cultures with plasma of rBPI₂₃-treated phx rats, α CD14 MAb, rBPI₂₃, and polymyxin B did not significantly alter the levels of TNF- α (Figure 5B).

Similar results were obtained when IL-6 or IL-8 were measured in the culture supernatants. Again, plasma of control-treated rats taken at $t = 1$ and $t = 2$ hours yielded significantly higher levels of these cytokines in the supernatant than those of their preoperative samples or phx plasma during rBPI₂₃ treatment. These elevated levels could be significantly diminished by adding α CD14 MAb, rBPI₂₃, and to a lesser extent polymyxin B to the culture (data not shown).

Discussion

More than 20 years ago, Gans et al³² suggested the involvement of endogenous endotoxins in the development of hemodynamic alterations during acute liver failure. These authors reported an immediate hypotension accompanied by a decrease in CO and heart rate in dogs that underwent a radical liver resection. These changes were delayed by pretreating the animals with orally administered neomycin, a broad spectrum antibiotic.³² Liver failure induced by




Figure 5. Inhibition of endotoxin-induced stimulation of human whole blood cultured with ex vivo rat plasma. Induction of TNF- α in cultures of human whole blood by PHX-CON plasma obtained 1 hour after resection is inhibited by α CD14, rBPI₂₃, or polymyxin B. (A) Cultures of PHX-CON plasma taken at $t = 1$ hour were incubated in the presence of 5 μ g/ml α CD14 MAb (○), 2 μ g/ml rBPI₂₃ (□), 2 ng/ml polymyxin B (▼), or PBS (■). TNF- α levels obtained with baseline ($t = 0$ hours) PHX-CON plasma are shown for comparison (+). (B) Plasma from RBPI₂₃-treated animals was incubated with human whole blood in the presence of α CD14 MAb (○), rBPI₂₃ (□), polymyxin B (▼), or PBS (▽). Note the difference in scale of the y-axis of A and B.

phx has previously been found to result in endotoxemia, as assessed using a limulus assay, which was prevented by enteral administration of nonspecific endotoxin-binding agents.¹⁴ Others have suggested that endotoxemia secondary to failure of hepatic phagocytic function contributes to the pathogenesis of infectious complications^{3,7,9} or has an additive effect on the pathology of the liver itself, and contributes to extrahepatic complications.^{14,33} However, experimental evidence for this notion is lacking. Whether circulating endotoxins after liver failure may induce inflammatory responses leading to clinical manifestations of infection is not known.

In the present study, we show that liver failure due to phx in rats induces an inflammatory response, reflected by the course of plasma levels of TNF and IL-6, biochemical, and hemodynamic alterations, and morphological changes in the lungs. These inflammatory manifestations after liver failure were strongly reduced by intervention with rBPI₂₃, an endotoxin-neutralizing protein, suggesting this response is due to the appearance of endotoxins in the circulation. Based upon earlier observations in this model, these endotoxins most likely were derived from the gut.¹⁴

Development of a systemic inflammatory response during liver failure was evidenced by the appearance of proinflammatory cytokines in the circulation. After the induction of liver failure, TNF levels peaked at 2 hours, resembling the response after a

bacterial or endotoxin challenge.³⁴⁻³⁶ In these models, IL-6 reaches its nadir at 3 hours after a mild challenge, whereas after a more severe challenge such as a lethal dose of live *E. coli*, levels of this cytokine still increase after 6 hours.³⁷ In the present study, IL-6 levels at 4 hours after hepatectomy were still increasing, which would be consistent with a response after a severe challenge. During rBPI₂₃ treatment of hepatectomized rats, release of both TNF and IL-6 was effectively blunted. At 24 hours, the IL-6 levels that we measured in the group of hepatectomized animals that were sacrificed for histological studies still were significantly elevated compared with sham animals (423 ± 96 and 162 ± 27 U/ml, respectively; $P < 0.05$), suggesting ongoing IL-6 production beyond 4 hours after the induction of liver failure. In contrast, IL-6 levels in rBPI₂₃-treated hepatectomized animals (207 ± 30 U/ml; $P < 0.05$ versus PHX-CON and $P = NS$ versus SHAM) were reduced to near sham levels.

The observed dysfunction of the various organs during liver failure induced by phx was similar to those occurring in sepsis or sepsis-like conditions. We found that liver failure led to the development of a hypodynamic circulatory state as evidenced by lowering of blood pressure, CO, and heart rate. These derangements in systemic hemodynamics resembled those seen shortly after exogenously administered endotoxin^{38,39} or during polymicrobial sepsis.⁴⁰ Also, an early increase in hematocrit was

observed, indicating hypovolemia presumably due to an increase in vasopermeability. Renal dysfunction, as demonstrated by rising creatinin and urea, changes in WBC numbers and glucose levels, and acidosis all are signs of a systemic inflammatory response syndrome and sepsis.⁴¹⁻⁴⁴ Administration of rBPI₂₃ preserved blood pressure, CO, and heart rate after liver resection. In addition, renal dysfunction; metabolic acidosis; and changes in total WBC numbers, hematocrit and glucose levels were not observed or diminished in hepatectomized animals that were treated with rBPI₂₃.

Signs of liver failure such as elevated plasma levels of hepatic enzymes and ammonia also could be due to this inflammatory response. However, in our model, liver failure more likely was primarily related to the surgical procedure, because an early rise in transaminases and ammonia was not affected by rBPI₂₃ treatment (Table 1). In additional experiments, we found that transaminase and ammonia levels 24 hours after liver resection were indeed reduced by rBPI₂₃, indicating superimposed liver failure related to endotoxins.⁴⁵

The lungs are frequently affected during a systemic inflammatory response. We therefore performed histological studies of this organ to further substantiate such a response during liver failure. Accumulation of neutrophils in the pulmonary microcirculation is a prominent feature in the lungs during endotoxemia, and it is known to precede lung injury,^{46,47} characterized by pulmonary edema and increased alveocapillary permeability.^{48,49} The structural changes we found in the lungs 24 hours after the induction of liver failure resembled those seen 5 hours after *E. coli*-induced shock,⁵⁰ but were less severe than those seen 26 hours after a lethal endotoxin infusion,⁵¹ suggesting less advanced although significant lung injury. Importantly, rBPI₂₃ infusion prevented these morphological changes in rat lungs after phx.

The inflammatory response as observed during hepatectomy-induced liver failure, was not likely related to mere surgery. Although minor or major surgery may increase levels of proinflammatory cytokines,^{12,52} the sham-operated animals in our experiments did not show a severe systemic inflammatory response, as defined by significant changes in hemodynamics, organ dysfunction, and high circulating levels of inflammatory mediators. The early, mild increase in levels of TNF and IL-6, from $t = 1$ hour on, were not likely due to the effects of endotoxins, because rBPI₂₃ treatment in sham animals did not alter these cytokine levels. For IL-6, such an increase in its plasma levels after laparotomy has

been described before, possibly related to a stress reaction and/or tissue injury.⁵³ We have no explanation for the observation that TNF levels in rBPI₂₃-treated phx rats were even lower than those in rBPI₂₃-treated sham rats. Possibly, this difference can be attributed to an endogenous anti-inflammatory response involving cytokines such as IL-10 and IL-1ra, which are known to be released after an endotoxin challenge.^{54,55}

Besides evaluating the *in vivo* effects of rBPI₂₃ treatment, we performed *in vitro* experiments with rat plasma and human whole blood to substantiate the presence of endotoxins in the circulation. We aimed to assess the bioactive properties of circulating endotoxins by evaluating their capacity to induce the production of cytokines in blood from healthy humans. We used a human blood system, as we only had antibodies against human CD14, the receptor for endotoxin on monocytes, available, and not antibodies against its counterpart in rats. Moreover, the use of human blood allowed the use of highly sensitive immunosorbent assays that are specific for human cytokines and do not cross-react with rat cytokines. The results showed that after phx, *ex vivo* rat plasma induced high levels of TNF, IL-6, and IL-8 in human blood cultures. This stimulatory capacity of phx rat plasma was evident as early as 1 hour after the resection, thus preceding the endogenous cytokine response of these animals. Cytokine release in human whole blood cultures by hepatectomized rat plasma could be blocked by α CD14 MAb, polymyxin B, and rBPI₂₃, in agreement with endotoxins being present in hepatectomized rat plasma. This *in vitro* cytokine release induced by plasma of hepatectomized rats and subsequent blockade showed a similar pattern as that of LPS added to normal rat plasma. Further results were consistent with the *in vivo* experiments, as plasma of rBPI₂₃-treated animals induced low levels of cytokines in culture, equivalent to plasma of sham animals, which were near background levels. The observation that the stimulatory capacity of phx plasma taken 2 hours after the resection was less than that of plasma taken after 1 hour might suggest that the endotoxemia was limited to the first hours of liver failure. Because the clearance capacity of the liver is not restored at that time,³ we postulate that translocation of enteric endotoxins is not a continuous but rather a pulsatile process. After 24 to 48 hours after a liver resection in rats, liver cell proliferation is maximal and the amount of functional liver tissue partly restored,^{3,56} illustrating that in this model liver failure is self-limiting.

In conclusion, we have shown that liver failure due to phx induces a systemic endotoxemia leading to

the development of a systemic inflammatory response. This response and its clinical, hemodynamic, and biochemical sequelae were blunted by the administration of the recombinant N-terminal fragment of BPI. These findings may lead to a better understanding of extrahepatic complications during liver failure. Further studies are needed to establish whether clinical interventions based on this pathogenic mechanism may reduce the morbidity or mortality related to liver failure or liver surgery in humans.

Acknowledgments

The authors wish to gratefully acknowledge Dr. Walter Fiers and Maureen van den Hemel (Department of Molecular Biology, University of Ghent, Belgium); Els de Groot and Dr. Patty Jansen (Central Lab of the Red Cross Blood Transfusion Services, Amsterdam); and Irene Straatsburg and Dr. Ron van Noorden (Department of Histology and Cell Biology, Academic Medical Center, University of Amsterdam) for their expertise and guidance. Assistance with chemical and hematological analysis was kindly provided by Jolanda van der Mark. We thank the Department of Pathology, Free University Hospital Amsterdam, for their technical assistance in preparing the tissue sections, and Jan Peeterse (Laboratory of Cell Biology, University of Amsterdam) for his photographic artwork.

References

1. Matuschak GM, Rinaldo JE: Organ system interactions in the adult respiratory distress syndrome: role of the liver in host defense. *Chest* 1988, 94:400–408
2. Biozzi G, Stiffel C: The physiopathology of the reticuloendothelial cells of the liver and spleen. *Prog Liver Dis* 1965, 2:166–191
3. Gross K, Katz S, Dunn SP, Cikrit D, Rosenthal R, Grosfeld JL: Bacterial clearance in the intact and regenerating liver. *J Ped Surg* 1985, 20:320–323
4. Andersson R, Foss A: Abdominal sepsis following liver resection in the rat. *Hepato-Gastroenterology* 1991, 38:547–549
5. Vo NM, Chi DS: Effect of hepatectomy on the reticuloendothelial system of septic rats. *J Trauma* 1988, 28:852–854
6. Callery MP, Kamei T, Flye MW: Kupffer cell blockade increases mortality during intra-abdominal sepsis despite improving systemic immunity. *Arch Surg* 1990, 125:36–41
7. Gaeta GB, Perna P, Adinolfi LE: Endotoxemia in a series of 104 patients with chronic liver diseases: prevalence and significance. *Digestion* 1982, 23:239–244
8. Bigatello LM, Broitman SA, Fattori L, Di Paoli M, Pontello M, Bevilacqua G, Nespoli A: Endotoxemia, encephalopathy, and mortality in cirrhotic patients. *Am J Gastroenterol* 1987, 82:12–15
9. Wilkinson SP, Arroyo V, Gazzard BG, Moodie H, Williams R: Relation of renal impairment and hemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. *Lancet* 1974, i:521–524
10. Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Gimson A, Casewell M, Fagan E, Williams R: Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. *Hepatology* 1990, 11:49–53
11. Lumsden AB, Henderson JM, Kutner MH: Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. *Hepatology* 1988, 8:232–236
12. Wortel CH, Van Deventer SJH, Aarden LA, Lygidakis NJ, Büller HR, Hoek FJ, Horikx J, Ten Cate JW: Interleukin-6 mediates host defense responses induced by abdominal surgery. *Surgery* 1993, 114:564–570
13. Stone MD, Benotti PN: Preoperative and postoperative care. *Surg Clin N Am* 1989, 69:385–392
14. Van Leeuwen PAM, Hong RW, Rounds JD, Rodrick ML, Wilmore DW: Hepatic failure and coma after liver resection is reversed by manipulation of gut contents: the role of endotoxin. *Surgery* 1991, 110:169–175
15. Gazzano-Santoro H, Parent JB, Grinna L, Horwitz A, Parsons T, Theofan G, Elsbach P, Weiss J, Conlon PJ: High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. *Infect Immun* 1992, 60:4754–4761
16. Weiss J, Elsbach P, Olsson I, Oderberg H: Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. *J Biol Chem* 1978, 253:2664–2672
17. Ooi CE, Weiss J, Doerfler ME, Elsbach P, Frangione B, Mannion B: A 25-kDa NH₂-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal-permeability-increasing protein. *J Biol Chem* 1987, 262:14891–14894
18. Weiss D, Elsbach P, Gazzano-Santoro H, Parent JB, Grinna L, Horwitz A, Theofan G: Bactericidal and endotoxin-neutralizing activities of the bactericidal/permeability-increasing protein and its bioactive N-terminal fragment. *Bacterial Endotoxin: Recognition and Effector Mechanisms*. Edited by J Levin, CR Alving, RS Munford, PL Stütz. New York, Elsevier Science Publishers BV, 1993, pp 103–112
19. Mészáros K, Aberle S, Dedrick R, Machovich R, Horwitz A, Birr C, Theofan G, Parent JB: Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein. *Blood* 1994, 83:2516–2525
20. Kohn FR, Ammons WS, Horwitz A, Grinna L, Theofan G, Weickmann J, Kung AHC: Protective effect of a recom-

- binant amino terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. *J Infect Dis* 1993, 168:1307-1310
21. Ammons WS, Kung AHC: Recombinant amino terminal fragment of bactericidal/permeability-increasing protein prevents hemodynamic responses to endotoxin. *Circ Shock* 1993, 41:176-184
 22. Higgins GM, Anderson RM: Experimental pathology of the liver. Restoration of the liver of the white rat following partial removal. *Arch Pathol* 1931, 2:186-202
 23. Malik AR, Kaplan JE, Saba TM: Reference sample method for cardiac output and regional blood flow determinations in the rat. *J Appl Physiol* 1976, 40:472-475
 24. Van Leeuwen PAM, Bading JR, Vydellingum NA, Younes RN, de Rooij P, Brennan M: Organ blood flow in Fischer-344 rats bearing MCA-induced sarcoma. *J Appl Physiol* 1991, 71:1674-1678
 25. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. *J Immunol Methods* 1986, 95:99-105
 26. Hansen MB, Nielsen SE, Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. *J Immunol Methods* 1989, 119:203-210
 27. Aarden LA, De Groot ER, Schaap OL, Lansdorp PM: Production of hybridoma growth factor by human monocytes. *Eur J Immunol* 1987, 17:1411-1416
 28. Helle M, Boeije L, Aarden LA: Functional discrimination between interleukin 6 and interleukin 1. *Eur J Immunol* 1988, 18:1535-1540
 29. Helle M, Boeije L, De Groot ER, De Vos A, Aarden LA: Sensitive ELISA for interleukin-6: detection of IL-6 in biological fluids: synovial fluids and sera. *J Immunol Methods* 1991, 38:47-56
 30. Brakenhoff JPJ, De Groot ER, Evers RF, Pannekoek H, Aarden LA: Molecular cloning and expression of hybridoma growth factor in *Escherichia coli*. *J Immunol* 1987, 39:4116-4121
 31. Hack CE, Hart M: Strack van Schijndel RJM, Eerenberg AJM, Nuijens JH, Thijs LG, Aarden LA: Interleukin-8 in sepsis: relation to shock and inflammatory mediators. *Infect Immunity* 1992, 60:2835-2842
 32. Gans H, Mori K, Lindsey E, Kaster B, Richter D, Quinlan R, Dineen PA, Tan BH: Septicemia as a manifestation of acute liver failure. *Surg Gynecol Obstet* 1971, 132:783-790
 33. Nolan JP: Endotoxin, reticuloendothelial function, and liver injury. *Hepatology* 1981, 1:458-465
 34. Fong Y, Lowry SF: Tumor necrosis factor in the pathophysiology of infection and sepsis. *Clin Immunol Immunopathol* 1990, 55:157-170
 35. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, Thompson RC, Lowry SF, Moldawer LL: Interleukin-1 receptor blockade improves survival and hemodynamic performance in *Escherichia coli* septic shock, but fails to alter host responses to sublethal endotoxemia. *J Clin Invest* 1992, 89:1551-1557
 36. Van Deventer SJH, Büller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxaemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathway. *Blood* 1990, 76:2520-2526
 37. Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R, Hinshaw L, Taylor FB Jr: Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal *Escherichia coli*. *Circ Shock* 1991, 33:84-91
 38. Van Lambalgen AA: Van den Bos GC, Thijs LG: Changes in regional plasma extravasation in rats following endotoxin infusion. *Microvasc Res* 1987, 34:116-132
 39. Mulder MF, Van Lambalgen AA, Van Kraats AA, Schefler PG, Bouman AA: Van den Bos GC, Thijs LG: Systemic and regional hemodynamic changes during endotoxin or platelet activating factor (PAF) induced shock in rats. *Circ Shock* 1993, 41:221-229
 40. Alexander HR, Doherty GM, Venzon DJ, Merino MJ, Fraker DL, Norton JA: Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. *Surgery* 1992, 112:188-194
 41. Van Lambalgen AA, Van Kraats AA: Van den Bos GC, Stel HV, Straub J, Donker AJM, Thijs LG: Renal function and metabolism during endotoxemia in rats: role of hypoperfusion. *Circ Shock* 1991, 35:164-173
 42. Tran DD, Groeneveld ABJ: Van der Meulen J, Nauta JJP, Strack van Schijndel RJM, Thijs LG: Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. *Crit Care Med* 1990, 18:474-479
 43. Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG, Lynch EA, Ye K, Poutsika DD, Vannier E, Shapiro L, Pribble JP, Stiles DM, Catalano MA, Wolff SM, Dinarello CA: Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. *Blood* 1993, 82:2985-2990
 44. Bastiaans JC, Vleeming W: The effect of compensation of acidosis on survival in endotoxin shock. *Adv Shock Res* 1981, 6:163-174
 45. Boermeester MA, Straatsburg IH, Houdijk APJ, Meyer C, Frederiks WM, Wesdorp RIC, Van Noorden CJF, Van Leeuwen PAM: Endotoxin and Interleukin-1 related hepatic inflammatory response promotes liver failure after partial hepatectomy. *Hepatology* 1995 (in press)
 46. Brigham KL, Meyrick B: Endotoxin and lung injury. *Am Rev Respir Dis* 1986, 133:913-927
 47. Bloom RJ, Simon LM, Benitz WE: Endotoxin and pulmonary cell injury. *Surg Gynecol Obstet* 1988, 167:92-98
 48. Simons RK, Maier RV, Lennard ES: Neutrophil function in a rat model of endotoxin-induced lung injury. *Arch Surg* 1987, 122:197-203
 49. Welbourn CRB, Young Y: Endotoxin, septic shock, and

- acute lung injury: neutrophils, macrophages and inflammatory mediators. *Br J Surg* 1992, 79:998–1003
50. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA: A specific receptor antagonist for interleukin 1 prevents *Escherichia coli*-induced shock in rabbits. *FASEB J* 1991, 5:338–343
51. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: IL-1 receptor antagonist reduces mortality from endotoxin shock. *Nature* 1990, 248:550–552
52. Baigrai RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ: Systemic cytokine response after major surgery. *Br J Surg* 1992, 79:757–760
53. Van Gool J, Van Vugt H, Helle M, Aarden LA: The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. *Clin Immunol Immunopathol* 1990, 57:200–210
54. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, De Vries JE: Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. *J Exp Med* 1991, 174:1209–1220
55. Fischer E, Van Zee KJ, Marano MA, Rock CS, Kenney JS, Poutsika DD, Dinarello CA, Lowry SF, Moldawer LL: Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. *Blood* 1992, 79:2196–2200
56. Michalopoulos GK: Liver regeneration: molecular mechanisms of growth control. *FASEB J* 1990, 4:176–187